RNAlead has developed a proprietary technology, derived from vectors, to encapsulate RNA of interest to be injected in patients to enable them to benefit from RNA treatment.

​

It is an alternative to LNP technology, with an independent proprietary IP, more effective (>30x), and safer, without genome insertion and low immunogenicity.

The field of application are all therapies leveraging RNA: gene therapy, genome edition, cell reprogramming, vaccination, immunotherapy